Tuberculosis and Respiratory Diseases

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis

Seung Sook Paik, In Kyoung Hwang, Myung Jae Park, Seung Hyeun Lee

Tuberc Respir Dis. 2018;81(2):148-155. Published online March 7, 2018
DOI: https://doi.org/10.4046/trd.2017.0090

P2.03-020 Pemetrexed Continuation Maintenance versus Conventional Platinum-based Doublet Chemotherapy in EGFR-negative Lung Adenocarcinoma: Retrospective Analysis

I.K. Hwang, S.S. Paik, M.J. Park, S.H. Lee

Journal of Thoracic Oncology. 2017;12(11):S2135

Link1 Link2

Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis

Seung Sook Paik, In Kyoung Hwang, Myung Jae Park, Seung Hyeun Lee

Tuberculosis and Respiratory Diseases. 2018;81(2):148

Link1 Link2 Link3

A cross-trial comparison of pemetrexed-platinum followed by pemetrexed continuation maintenance versus gemcitabine-cisplatin without maintenance in chemotherapy-naive patients with advanced nonsquamous non-small-cell lung cancer

Y.-L. Wu, B. Zhang, X. Wang, M. Orlando, H. Chi

Annals of Oncology. 2016;27:vi445

Link1 Link2 Link3

Pemetrexed versus best supportive care following platinum-based doublet chemotherapy for patients with advanced nonsmall cell nonsquamous lung cancer

P. Kumari

Annals of Oncology. 2017;28:x139

Link1 Link2 Link3

Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience

Liping Lin, Juanjuan Zhao, Jiazhu Hu, Fuxi Huang, Jianjun Han, Yan He, Xiaolong Cao

OncoTargets and Therapy. 2016;Volume 9:6305-6314

Link1 Link2

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma

Xiaoyu Zhai, Qiwen Zheng, Lu Yang, Yixiang Zhu, Junling Li, Yutao Liu, Ziping Wang

Scientific Reports. 2017;7(1):

Link1

Link2 Link3

Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis

Nikolaj Frost, Tamar Zhamurashvili, Maximilian von Laffert, Frederick Klauschen, Christoph Ruwwe-Glösenkamp, Matthias Raspe, Matthias Brunn, Sebastian Ochsenreither, Bettina Temmesfeld-Wollbrück, Norbert Suttorp, Christian Grohé, Martin Witzenrath

Clinical Lung Cancer. 2020;21(6):e607-e621

Link1 Link2

66: Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum non-pemetrexed doublet chemotherapy

R. Marshall, M. Kakoudaki, S.J. Danson, P.M. Fisher, M.Q. Hatton, C.E. Lee, T. Das, E. Bates, P. Woll, F. Taylor

Lung Cancer. 2017;103:S31

Link1 Link2

P2.03a-068 Impact of Platinum/Pemetrexed versus Other Platinum-Based Regimens on Adjuvant Chemotherapy in Resected Adenocarcinoma Lung Cancer

Xiaoyu Zhai, Wang Ziping, Lu Yang, Yixiang Zhu, Junling Li

Journal of Thoracic Oncology. 2017;12(1):S930-S931

Link1 Link2

Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis

Yin Shi, Rui Pei, Shao Liu

Frontiers in Oncology. 2022;12:

Link1